Angiotech to webcast conference call discussing fourth quarter 2005 financial results
24 Februar 2006 - 8:55PM
PR Newswire (US)
VANCOUVER, Feb. 24 /PRNewswire-FirstCall/ -- Angiotech
Pharmaceuticals, Inc. (NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), will
webcast its conference call discussing financial results for the
fourth quarter ended December 31, 2005 on Thursday, March 2nd, 2006
at 2:00 PM PST (5:00 PM EST). The webcast will be available to all
interested parties through Angiotech's website at
http://www.angiotech.com/ under Investor Relations or by dialing
toll-free in North America to 866-362-4820 (International callers
please dial 617-597-5345) and entering Passcode 19190201. To ensure
a timely connection to the webcast it is recommended that users
register approximately 15 minutes before the conference call. A
recording of the call will be available until Thursday, March 10th
by dialing toll-free in North America 888-286-8010 (International
at 617-801-6888) and entering Passcode 32435888. A press release
will be issued prior to the conference call. The conference call
will be hosted by William Hunter, President and Chief Executive
Officer, and Thomas Bailey, Chief Financial Officer. The webcast
will be available for seven days on the Angiotech website. About
Angiotech Pharmaceuticals Vancouver-based Angiotech
Pharmaceuticals, Inc. is a specialty pharmaceutical company
pioneering the combination of pharmaceutical compounds with medical
devices and biomaterials to both create novel solutions for poorly
addressed disease states and improve surgical outcomes. To find out
more about Angiotech Pharmaceuticals, Inc.
(NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), please visit our website at
http://www.angiotech.com/. Statements contained herein that are not
based on historical or current fact, including without limitation
statements containing the words "anticipates," "believes," "may,"
"continue," "estimate," "expects," and "will" and words of similar
import, constitute "forward-looking statements" within the meaning
of the U.S. Private Securities Litigation Reform Act of 1995. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results,
events or developments to be materially different from any future
results, events or developments expressed or implied by such
forward-looking statements. Such factors include, among others, the
following: general economic and business conditions, both
nationally and in the regions in which the Company operates;
technology changes; competition; changes in business strategy or
development plans; the ability to attract and retain qualified
personnel; existing governmental regulations and changes in, or the
failure to comply with, governmental regulations; liability and
other claims asserted against the Company; and other factors
referenced in the Company's filings with the United States
Securities and Exchange Commission or the Canadian securities
regulators. Given these uncertainties, readers are cautioned not to
place undue reliance on such forward-looking statements. The
Company does not assume the obligation to update any
forward-looking statements. FOR ADDITIONAL INFORMATION: Analysts
and Investors: Rui Avelar, Chief Medical Officer Angiotech
Pharmaceuticals, Inc. (604) 221-7676 ext 6933 Media: Colleen
Beauregard Waggener Edstrom Bioscience (503) 443-7863, Email:
DATASOURCE: Angiotech Pharmaceuticals, Inc. CONTACT: Analysts and
Investors: Rui Avelar, Chief Medical Officer, Angiotech
Pharmaceuticals, Inc., (604) 221-7676 ext 6933; Media: Colleen
Beauregard, Waggener Edstrom Bioscience, (503) 443-7863, Email:
Copyright
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
Echtzeit-Nachrichten über Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ): 0 Nachrichtenartikel
Weitere Angiotech Pharmaceuticals - Common Shares (MM) News-Artikel